![]() |
| Electronic glasses |
Science Corporation has received European regulatory approval for a medical device designed to restore vision in patients.
Science Corporation, a company specializing in the development of brain-computer interfaces (BCI), has secured European regulatory approval for a new medical device designed to restore vision in patients who have lost it due to age-related macular degeneration.
The company announced that its device, named PRIMA, has also received a special designation from the U.S. Food and Drug Administration (FDA) a move that paves the way for an expedited review process, potentially accelerating its use in treating two rare forms of blindness.
Millions of people worldwide suffer from age-related macular degeneration, a disease that damages light-sensitive cells in the retina, making reading and recognizing faces extremely difficult, according to a report published by TechCrunch and reviewed by Al Arabiya Business.
The PRIMA system relies on a minimally invasive surgical procedure lasting approximately one hour, during which a tiny electronic chip is implanted behind the eye. Following the procedure, the patient wears glasses equipped with a camera that captures the surrounding scene and transmits images to the chip; this stimulates the retina to provide functional vision, helping patients regain some of their ability to see.
Max Hodak, the company’s founder and CEO, stated that the device has made a genuine difference in patients' lives, noting that one patient in France was able to read an entire 300-page novel, while others successfully solved crossword puzzles and Sudoku, and one even drew a picture of the Sydney Opera House.
Hodak is known as a co-founder and former president of Neuralink; he left the company in 2021 to found Science Corporation, aiming to develop a new generation of brain-computer interfaces based on integrating electronic chips with living cells.
Hodak explained that the company recognized early on the need for a sustainable business model to fund the development of its future technologies, noting that the sector requires companies capable of generating strong revenue to avoid stagnation that could hinder innovation. He added that treating vision loss serves as the commercial foundation that will finance the company’s long-term research into advanced neural interfaces.
After evaluating various technologies, Science Corp determined that the French company Pixium Vision possessed the most suitable solution; consequently, it acquired the firm in 2024. It then focused on refining the product and developing the necessary technical documentation in preparation for securing regulatory approvals and launching the device on the market.
The company anticipates that the price of each PRIMA device will reach hundreds of thousands of dollars, and it is currently negotiating with insurance companies and healthcare providers in Europe to secure coverage for the treatment costs. Preparations are underway to launch the device in Germany where clinical trials were conducted with the first commercial procedure potentially taking place this coming September.
Science Corporation, a company specializing in the development of brain-computer interfaces (BCI), has secured European regulatory approval for a new medical device designed to restore vision in patients who have lost it due to age-related macular degeneration.
The company announced that its device, named PRIMA, has also received a special designation from the U.S. Food and Drug Administration (FDA) a move that paves the way for an expedited review process, potentially accelerating its use in treating two rare forms of blindness.
Millions of people worldwide suffer from age-related macular degeneration, a disease that damages light-sensitive cells in the retina, making reading and recognizing faces extremely difficult, according to a report published by TechCrunch and reviewed by Al Arabiya Business.
The PRIMA system relies on a minimally invasive surgical procedure lasting approximately one hour, during which a tiny electronic chip is implanted behind the eye. Following the procedure, the patient wears glasses equipped with a camera that captures the surrounding scene and transmits images to the chip; this stimulates the retina to provide functional vision, helping patients regain some of their ability to see.
Max Hodak, the company’s founder and CEO, stated that the device has made a genuine difference in patients' lives, noting that one patient in France was able to read an entire 300-page novel, while others successfully solved crossword puzzles and Sudoku, and one even drew a picture of the Sydney Opera House.
Hodak is known as a co-founder and former president of Neuralink; he left the company in 2021 to found Science Corporation, aiming to develop a new generation of brain-computer interfaces based on integrating electronic chips with living cells.
Hodak explained that the company recognized early on the need for a sustainable business model to fund the development of its future technologies, noting that the sector requires companies capable of generating strong revenue to avoid stagnation that could hinder innovation. He added that treating vision loss serves as the commercial foundation that will finance the company’s long-term research into advanced neural interfaces.
After evaluating various technologies, Science Corp determined that the French company Pixium Vision possessed the most suitable solution; consequently, it acquired the firm in 2024. It then focused on refining the product and developing the necessary technical documentation in preparation for securing regulatory approvals and launching the device on the market.
The company anticipates that the price of each PRIMA device will reach hundreds of thousands of dollars, and it is currently negotiating with insurance companies and healthcare providers in Europe to secure coverage for the treatment costs. Preparations are underway to launch the device in Germany where clinical trials were conducted with the first commercial procedure potentially taking place this coming September.

0 Comments